* MedImmune Inc., of Gaithersburg, Md., signed an exclusiveworldwide license agreement with the German Cancer ResearchCenter to obtain rights to intellectual property in the area of humanpapillomavirus vaccines.
* Vertex Pharmaceutical Inc., of Cambridge, Mass., began a Phase IItrial of VX-710, in combination with doxorubicin, in liver cancerpatients. The drug is being developed to resensitize tumor cells tochemotherapeutic agents to combat multidrug resistance.
* Zonagen Inc., of The Woodlands, Texas, submitted aninvestigational new drug application related to a Phase III programfor Vasomax as a treatment for erectile dysfunction.
* Paracelsian Inc., of Ithaca, N.Y., received a $2 million privateequity investment. The company sold both common stock andwarrants to purchase common stock at between $2.75 and $4.50 pershare.
* MicroCarb Inc., of Gaithersburg, Md., completed a Phase I trial ofits Campylobacter vaccine for gastroenteritis and diarrhea. The 30-volunteer study showed the vaccine to be safe and immunogenic.
* Cell Therapeutics Inc., of Seattle, said it is postponing its initialpublic offering due to unfavorable market conditions. The companydid not withdraw the registration statement filed on April 26, 1996.Cell Therapeutics is developing small molecules that modulate theproduction of cell membrane lipids called phosphatidic acids.
* Interferon Sciences Inc., of New Brunswick, N.J., began a Phase IIItrial of its injectable formulation of Interferon Alpha-n3, a naturalsource interferon, for HIV. The randomized, double-blind, placebo-controlled study will involve patients with CD4 T cell counts of atleast 250 cells per microliter and a viral burden of at least 2,000copies per milliliter. Patients may already be taking other antiviralagents.
(c) 1997 American Health Consultants. All rights reserved.